


Application No. 10/567,798
Amendment Dated August 6, 2008
Reply to Office Action of June 6, 2008

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (previously presented) A compound of formula (1):



A is phenylene or heteroarylene;

n is 0, 1 or 2;

m is 0, 1 or 2;

R¹ is independently selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, N-(1-4C)alkylcarbamoyl, N,N-((1-4C)alkyl)₂carbamoyl, sulphamoyl, N-(1-4C)alkylsulphamoyl, N,N-((1-4C)alkyl)₂sulphamoyl, -S(O)_b(1-4C)alkyl (wherein b is 0,1,or 2), -OS(O)₂(1-4C)alkyl, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy, (1-4C)alkanoyl, (1-4C)alkanoyloxy, hydroxy(1-4C)alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy and -NHSO₂(1-4C)alkyl;

or, when n is 2, the two R¹ groups, together with the carbon atoms of A to which they are attached, may form a 4 to 7 membered saturated ring, optionally containing 1 or 2 heteroatoms independently selected from O, S and N, and optionally being substituted by one or two methyl groups;

one of R² and R³ is selected from R_{Na}, and the other is selected from R_{Nb};

R_{Na}: (1-3C)alkyl, halo(1-3C)alkyl, dihalo(1-3)alkyl, trifluoromethyl, hydroxy(1-3C)alkyl, dihydroxy(2-3C)alkyl, cyano(1-3C)alkyl (optionally substituted on alkyl with hydroxy), methoxymethyl, ethoxymethyl, methoxyethyl, methoxymethoxymethyl, dimethoxyethyl, (hydroxy)(methoxy)ethyl, 5- and 6-membered acetals and mono- and di-methyl derivatives thereof, (amino)(hydroxy)(2-3C)alkyl, (aminocarbonyl)(hydroxy)(2-3C)alkyl, (methylaminocarbonyl)(hydroxy)(2-3C)alkyl, (dimethylaminocarbonyl)(hydroxy)(2-3C)alkyl,

Application No. 10/567,798
Amendment Dated August 6, 2008
Reply to Office Action of June 6, 2008

(methylcarbonylamino)(hydroxy)(2-3C)alkyl, (methylS(O)_p-(hydroxy)(2-3C)alkyl (wherein p is 0, 1 or 2);

R_{Nb}: (1-4C)alkyl, halo(1-4C)alkyl, dihalo(1-4C)alkyl, trifluoromethyl, hydroxy(1-4C)alkyl, dihydroxy(2-4C)alkyl, trihydroxy(3-4C)alkyl, cyano(1-4C)alkyl (optionally substituted on alkyl with hydroxy), (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkoxy(1-4C)alkyl, di[(1-4C)alkoxy](2-4C)alkyl, (hydroxy)[(1-4C)alkoxy](2-4C)alkyl, 5- and 6-membered acetals and mono- and di-methyl derivatives thereof, (amino)(hydroxy)(2-4C)alkyl, (aminocarbonyl)(hydroxy)(2-4C)alkyl, ((1-4C)alkylaminocarbonyl)(hydroxy)(2-4C)alkyl, (di(1-4C)alkylaminocarbonyl)(hydroxy)(2-4C)alkyl, ((1-4C)alkylcarbonylamino)(hydroxy)(2-4C)alkyl, ((1-4C)alkylS(O)_p-(hydroxy)(2-4C)alkyl (wherein p is 0, 1 or 2);

wherein any alkyl or alkoxy group within any group in R_{NA} and R_{NB} may also optionally be substituted on an available carbon atom with a hydroxy group (provided that said carbon atom is not already substituted by a group linked by a heteroatom);

provided that if R² is (1-3C)alkyl or (1-4C)alkyl then R³ is not (1-4C)alkyl or (1-3C)alkyl;

R⁴ is independently selected from halo, nitro, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy and (1-4C)alkanoyl;

or a pharmaceutically acceptable salt or pro-drug thereof.

2. (previously presented) A compound of formula (1) as claimed in Claim 1, or a pharmaceutically acceptable salt or pro-drug thereof, wherein R² is selected from R_{NA}, and R³ is selected from R_{Nb}, wherein R_{NA} and R_{Nb} are as defined in Claim 1.

3. (previously presented) A compound of formula (1) as claimed in Claim 1 or a pharmaceutically acceptable salt or pro-drug thereof, wherein A is phenylene.

4. (previously presented) A compound of formula (1) as claimed in Claim 1, or a pharmaceutically acceptable salt or pro-drug thereof, wherein n is 0.


5. (previously presented) A compound of formula (1) as claimed Claim[[s]] 1, or a pharmaceutically acceptable salt or pro-drug thereof, wherein m is 0 or 1.

Application No. 10/567,798
Amendment Dated August 6, 2008
Reply to Office Action of June 6, 2008

6. (previously presented) A compound of formula (1) as claimed in Claim1, or a pharmaceutically acceptable salt or pro-drug thereof, wherein R⁴ is methyl, chloro or fluoro.

7. (previously presented) A compound of formula (1) as claimed in Claim1, or a pharmaceutically acceptable salt or pro-drug thereof, wherein R_{NA} is selected from (1-4C)alkyl, hydroxy(1-4C)alkyl, and (1-4C)alkoxy(1-4C)alkyl.

8. (previously presented) A compound of formula (1) as claimed in Claim1-or a pharmaceutically acceptable salt or pro-drug thereof, which is a compound of formula (1A):



wherein R¹ to R⁴, m and n are as defined in claim1


9. (previously presented) A pro-drug of a compound of formula (1) as claimed in Claim1, which pro-drug is an in-vivo hydrolysable ester.

10. (original) A pharmaceutical composition which comprises a compound of the formula (1), as claimed in claim 1, or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, in association with a pharmaceutically-acceptable diluent or carrier.

11–15. (cancelled)


16. (original) A process for the preparation of a compound of formula (1) as claimed in claim 1, which process comprises:

reacting an acid of the formula (2):



Application No. 10/567,798
Amendment Dated August 6, 2008
Reply to Office Action of June 6, 2008

or an activated derivative thereof; with an amine of formula (3):



and thereafter if necessary:

- i) converting a compound of the formula (1) into another compound of the formula (1);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

17. (previously presented) A compound of formula (1) as claimed Claim 1, or a pharmaceutically acceptable salt or pro-drug thereof, wherein m is 0 or 1 and R⁴ is methyl, chloro or fluoro.

18. (previously presented) A compound of formula (1), or a pharmaceutically acceptable salt or pro-drug thereof, selected from:

5-chloro-N-{(1*R*,2*R*)-1-[(2*S*)-2,3-dihydroxypropanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;

5-chloro-N-{(1*R*,2*R*)-1-[methyl(seryl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide hydrochloride;

N-{(1*R*,2*R*)-1-[(*N*-acetylseryl)(methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloro-1*H*-indole-2-carboxamide;

(2*S*)-N¹-((1*R*,2*R*)-2-{[(5-chloro-1*H*-indol-2-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*¹-methylpentanediamide;

(2*S*)-N¹-((1*R*,2*R*)-2-{[(5-fluoro-1*H*-indol-2-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*¹-methylpentanediamide;

5-chloro-N-{(1*R*,2*R*)-1-[(2*S*)-2-hydroxy-3-methoxypropanoyl] (methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;

5-fluoro-N-{(1*R*,2*R*)-1-[(2*S*)-2-hydroxy-3-methoxypropanoyl] (methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;

(2*S*)-N¹-((1*R*,2*R*)-2-{[(5-chloro-1*H*-indol-2-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*¹-methylsuccinamide;

Application No. 10/567,798
Amendment Dated August 6, 2008
Reply to Office Action of June 6, 2008

(2*S*)-*N*¹-((1*R,2R*)-2-[(5-fluoro-1*H*-indol-2-yl)carbonyl]amino)-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*¹-methylsuccinamide;
(2*S*)-2-hydroxy-*N*¹-{(1*R,2R*)-2-[(1*H*-indol-2-ylcarbonyl)amino]-2,3-dihydro-1*H*-inden-1-yl}-*N*¹-methylsuccinamide;
(2*S*)-2-hydroxy-*N*¹-methyl-*N*¹-((1*R,2R*)-2-[(5-methyl-1*H*-indol-2-yl)carbonyl]amino)-2,3-dihydro-1*H*-inden-1-yl)succinamide;
N-{(1*R,2R*)-1-[(2*S*)-2-hydroxybutanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-methyl-1*H*-indole-2-carboxamide;
5-fluoro-*N*-{(1*R,2R*)-1-[(2*S*)-2-hydroxybutanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;
N-{(1*R,2R*)-1-[(2*S*)-2-hydroxybutanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;
5-chloro-*N*-{(1*R,2R*)-1-[(2*S*)-2-hydroxybutanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;
N-{(1*R,2R*)-1-[(2*S*)-2,3-dihydroxypropanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-methyl-1*H*-indole-2-carboxamide;
5-chloro-*N*-{(1*R,2R*)-1-[glycoloyl(2-hydroxyethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;
5-chloro-*N*-{(1*R,2R*)-1-[(2*S*)-2-hydroxybutanoyl](2-hydroxyethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide; or
5-chloro-*N*-{(1*R,2R*)-1-[(2*R*)-2,3-dihydroxypropanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide.

19. (previously presented) A method of producing a glycogen phosphorylase inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.

20. (previously presented) A method of treating type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.

Application No. 10/567,798
Amendment Dated August 6, 2008
Reply to Office Action of June 6, 2008

21. (previously presented) A method of treating type 2 diabetes in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.